AstraZeneca s Local Anaesthetic
Selected Abstract
AstraZeneca's Local Anaesthetic Naropin Announced an Additional Approval for a New Route of Administration, Intrathecal (Spinal) use in the European Union (EU).
SDERTEaLJE, Sweden, March 3 /PRNewswire/ -- AstraZeneca announced today that its long-acting local anaesthetic Naropin(r) (ropivacaine) 5.0 mg/ml was recommended for approval in all EU member states for a new route of administration, intrathecal (spinal) administration. This is an extended clinical ... March 3, 2004; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
AstraZeneca's Local Anaesthetic Naropin Announced an Additional Approval for a New Route of Administration, Intrathecal (Spinal) use in the European Union (EU).
|
